First Tracks Biotherapeutics (TRAX) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $2.01B and a free-cash-flow yield of -5.6%. Nama's AI scorecard rates it Sell, 3.0 out of 10.
AI scorecard
Sell · 3.0/10
Negative, at the mild end of Sell. As of Nov 7, 2026.
Shariah screen
Can't Tell
A figure the screen needs is missing, so it can't tell.
Off its high
-4.5%
How far the last close sits under the highest price of the past five years.
Market cap
$2.01B
Trailing P/E
—
Price / book
10.0
Price / sales
—
FCF yield
-5.6%
Dividend yield
—
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
Revenue growth (YoY)
—
Revenue growth (3-yr annual)
—
EPS growth (YoY)
—
FCF/share growth (YoY)
—
Beta
—
Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology
TRAX earnings
Next report: Feb 23, 2027 (Q4 2026, EPS estimate -$0.76).
Beat the EPS estimate in 0 of 2 recent quarters.
Quarter
Reported
EPS
Estimate
Surprise
Revenue
Q3 2026
Nov 3, 2026
-$0.88
-$0.88
+0.0%
$0
Q2 2026
Aug 12, 2026
-$0.95
-$0.80
-18.8%
$0
TRAX analyst price target
Median target $70.00 from 12 analysts, ranging $57.00 – $100.00.
Nama's AI scorecard currently rates First Tracks Biotherapeutics Sell (3.0 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does TRAX report earnings?
First Tracks Biotherapeutics's next scheduled report is on Feb 23, 2027. Analysts expect EPS of -$0.76.
What is the TRAX price target?
The median analyst price target from 12 analysts is $70.00, with a range of $57.00 – $100.00.
Is TRAX Shariah compliant?
Nama's AAOIFI-style screen reads First Tracks Biotherapeutics as Can't Tell. A figure the screen needs is missing, so it can't tell.